Diabetes Drugs: Some Work Better Than Others
Not allِ diabetes drugs areِ equally effective atِ preventing death andِ heart disease overِ a decade-long period, a newِ study suggests.
Diabetes patients whoِ takeِ someِ versions ofِ drugs called insulin secretagogues areِ 20 toِ 33 percent moreِ likelyِ to die fromِ anyِ cause overِ a 10-year period thanِ patients whoِ takeِ the diabetes drug metformin, theِ study said.
Insulin secretagogues haveِ beenِ aroundِ since theِ 1950s andِ work byِ stimulating cells toِ produce insulin, whileِ metformin works byِ reducing excess sugar seenِ inِ Type 2 diabetes.
The study was published today (April 6) in the European Heart Journal.
The drugs’ effects
Schramm andِ her colleagues examined theِ health status ofِ 107,806 Danish people ages 20 andِ older whoِ wereِ beingِ treated withِ insulin secretagogues orِ metformin betweenِ 1997 andِ 2006.
More thanِ halfِ the people inِ the study wereِ onِ insulin secretagogues.
Researchers foundِ that people whoِ tookِ theِ insulin secretagogues glimepiride, glyburide, gliclazide andِ tolbutamide hadِ a greater risk ofِ havingِ a heart attack orِ stroke orِ dying fromِ anyِ cause duringِ the 10-year period, compared withِ thoseِ who tookِ onlyِ metformin.
Diabetes affects 8.3 percent ofِ the U.S.
Fifty-eight percent ofِ people withِ diabetes takeِ anِ oral medication, likeِ metformin andِ insulin secretagogues, toِ control theِ amount ofِ glucose inِ their blood, according toِ theِ NIH.
Darren McGuire, anِ associate professor ofِ cardiology atِ the University ofِ Texas Southwestern Medical Center atِ Dallas, whoِ wasِ notِ involved withِ theِ study.